Global Xeloda Market Size, by Application (Colon Cancer, Rectal Cancer, Breast Cancer, Gastric Cancer), by Drug Formulation (Tablets and Capsules), & Region - Key Manufacturers, Analysis, Growth Trends, and Forecast till 2026

  • Category : Healthcare and Pharma
  • |
  • ID : 1012238
  • |
  • Publishe Date : May 2019
  • |
  • No of Pages: 121
  • |
  • Publisher : Intellectual Research Partners

The Global Xeloda market was estimated to be valued at USD XX million in 2019 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026. Growth in prevalence of cancer, increase in demand for target drug therapy will drive the market in forecast period. However, high cost of capecitabine, adverse effects, presence of substitutes, such as raltitrexed and leucovorin, and stringent government regulations related to the safety and efficacy of capecitabine hinder the market growth.

The global xeloda market is primarily segmented based on different application, drug formulation, and regions.

On the basis of application, the market is split into:
* Colon Cancer
* Rectal Cancer
* Breast Cancer
* Gastric Cancer
* Other Applications

On the basis of drug formulation, the market is split into:
* Tablet
* Capsule

Moreover, the market is classified based on regions and countries as follows:
* North America- U.S., Canada
* Europe- U.K., France, Germany, Italy and Rest of Europe
* Asia-Pacific- China, Japan, India and Rest of Asia Pacific
* South America- Brazil, Mexico and Rest of South America
* Middle East & Africa- South Africa, Saudi Arabia and Rest of Middle East & Africa

Key Market Players:
The key players profiled in the market include:
* Dr Reddy Laboratories Ltd
* Fresenius SE & Co. KGaA
* Cipla Inc.
* Genentech, Inc.
* F Hoffmann-La Roche
* Sandoz
* Ranbaxy Laboratories Ltd.
* Zentiva N.V.
* Teva Pharmaceutical Industries Ltd.
* Accord Healthcare Ltd.

These enterprises are focusing on growth strategies, such as new product launches, expansions, acquisitions, and agreements & partnerships to expand their operations across the globe.

Key Benefits of the Report:
* Global, regional, country, application, and drug formulation market size and their forecast from 2015-2026
* Identification and detailed analysis on key market dynamics, such as, drivers, restraints, opportunities, and challenges influencing growth of the market
* Detailed analysis on industry outlook with market specific PESTLE, and supply chain to better understand the market and build expansion strategies
* Identification of key market players and comprehensively analyze their market share and core competencies, detailed financial positions, key products, and unique selling points
* Analysis on key players’ strategic initiatives and competitive developments, such as joint ventures, mergers, and new product launches in the market
* Expert interviews and their insights on market shift, current and future outlook, and factors impacting vendors’ short term and long term strategies
* Detailed insights on emerging regions, application, and drug formulation with qualitative and quantitative information and facts

Target Audience:
* Xelodas Manufacturers
* Traders, Importers, and Exporters
* Raw Material Suppliers and Distributors
* Research and Consulting Firms
* Government and Research Organizations
* Associations and Industry Bodies

Research Methodology:
The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective, such as, analyst reports of investment banks. The secondary research is the primary base of our study wherein we conducted extensive data mining, referring to verified data sources, such as, white papers, government and regulatory published articles, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end use trends and dynamics, and production capacity were taken into consideration. Different weightages have been assigned to these parameters and quantified their market impacts using the weighted average analysis to derive the market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs), which typically include:
* Manufacturers
* Suppliers
* Distributors
* Government Body & Associations
* Research Institutes

TABLE OF CONTENTS

1. Introduction

2. Research Methodology

3. Executive Summary

4. Global Xeloda Market Overview
4.1. Market Segmentation & Scope
4.2. Market Trends
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Supply Chain Analysis
4.3. Global Xeloda Market - Porter\'s Five Forces Analysis
4.4. Global Xeloda Market - PESTEL Analysis

5. Global Xeloda Market, by Application
5.1. Global Xeloda Market, Size and Forecast, 2015-2026
5.2. Global Xeloda Market, by Colon Cancer, 2015-2026
5.2.1. Key driving factors, trends and opportunities
5.2.2. Market size and forecast, 2015-2026
5.3. Global Xeloda Market, by Rectal Cancer 2015-2026
5.3.1. Key driving factors, trends and opportunities
5.3.2. Market size and forecast, 2015-2026
5.4. Global Xeloda Market, by Breast Cancer, 2015-2026
5.4.1. Key driving factors, trends and opportunities
5.4.2. Market size and forecast, 2015-2026
5.5. Global Xeloda Market, by Gastric Cancer, 2015-2026
5.5.1. Key driving factors, trends and opportunities
5.5.2. Market size and forecast, 2015-2026

6. Global Xeloda Market, by Drug Formulation
6.1. Global Xeloda Market, Size and Forecast, 2015-2026
6.2. Global Xeloda Market, for Tablet 2015-2026
6.2.1. Key driving factors, trends and opportunities
6.2.2. Market size and forecast, 2015-2026
6.3. Global Xeloda Market, for Capsule 2015-2026
6.3.1. Key driving factors, trends and opportunities
6.3.2. Market size and forecast, 2015-2026

7. Global Xeloda Market, by Region
7.1. Xeloda Market Regional Analysis, 2015-2026
7.2. Global Xeloda Market Revenue (USD Million) by Region, 2015-2026
7.3. North America Xeloda Market, 2015-2026
7.3.1. North America Xeloda Market Size and Forecast, 2015-2026
7.3.2. North America Xeloda Market by Country, 2015-2026
7.3.2.1. U.S. Xeloda Market, 2015-2026
7.3.2.2. Canada Xeloda Market, 2015-2026
7.4. Europe Xeloda Market, 2015-2026
7.4.1. Europe Xeloda Market Size and Forecast, 2015-2026
7.4.2. Europe Xeloda Market by Country, 2015-2026
7.4.2.1. Germany Xeloda Market, 2015-2026
7.4.2.2. France Xeloda Market, 2015-2026
7.4.2.3. Italy Xeloda Market, 2015-2026
7.4.2.4. UK Xeloda Market, 2015-2026
7.4.2.5. Spain Xeloda Market, 2015-2026
7.4.2.6. Rest of Europe Xeloda Market, 2015-2026
7.5. Asia Pacific Xeloda Market, 2015-2026
7.5.1. Asia Pacific Xeloda Market Size and Forecast, 2015-2026
7.5.2. Asia Pacific Xeloda Market by Country, 2015-2026
7.5.2.1. Japan Xeloda Market, 2015-2026
7.5.2.2. China Xeloda Market, 2015-2026
7.5.2.3. India Xeloda Market, 2015-2026
7.5.2.4. Rest of Asia Pacific Xeloda Market, 2015-2026
7.6. South America Xeloda Market, 2015-2026
7.6.1. South America Xeloda Market Size and Forecast, 2015-2026
7.6.2. South America Xeloda Market by Country, 2015-2026
7.6.2.1. Mexico Xeloda Market, 2015-2026
7.6.2.2. Brazil Xeloda Market, 2015-2026
7.6.2.3. Rest of South America Xeloda Market, 2015-2026
7.7. Middle East & Africa Xeloda Market, 2015-2026
7.7.1. Middle East & Africa Xeloda Market Size and Forecast, 2015-2026
7.7.2. Middle East & Africa Xeloda Market by Country, 2015-2026
7.7.2.1. Saudi Arabia Xeloda Market, 2015-2026
7.7.2.2. South Africa Xeloda Market, 2015-2026
7.7.2.3. Rest of Middle East & Africa Xeloda Market, 2015-2026

8. Competitive Landscape
8.1. Introduction
8.2. Market Share Analysis/Top Player Positioning, 2019

9. Company Profiles
9.1. Dr Reddy Laboratories Ltd
9.1.1. Company Overview
9.1.2. Financial Overview
9.1.3. Product Benchmarking
9.1.4. Key Developments
9.2. Dr Reddy Laboratories Ltd
9.2.1. Company Overview
9.2.2. Financial Overview
9.2.3. Product Benchmarking
9.2.4. Key Developments
9.3. Cipla Inc.
9.3.1. Company Overview
9.3.2. Financial Overview
9.3.3. Product Benchmarking
9.3.4. Key Developments
9.4. Genentech, Inc.
9.4.1. Company Overview
9.4.2. Financial Overview
9.4.3. Product Benchmarking
9.4.4. Key Developments
9.5. F. Hoffmann-La Roche
9.5.1. Company Overview
9.5.2. Financial Overview
9.5.3. Product Benchmarking
9.5.4. Key Developments
9.6. Sandoz
9.6.1. Company Overview
9.6.2. Financial Overview
9.6.3. Product Benchmarking
9.6.4. Key Developments
9.7. Ranbaxy Laboratories Ltd.
9.7.1. Company Overview
9.7.2. Financial Overview
9.7.3. Product Benchmarking
9.7.4. Key Developments
9.8. Zentiva N.V.
9.8.1. Company Overview
9.8.2. Financial Overview
9.8.3. Product Benchmarking
9.8.4. Key Developments
9.9. Teva Pharmaceutical LTD.
9.9.1. Company Overview
9.9.2. Financial Overview
9.9.3. Product Benchmarking
9.9.4. Key Developments
9.10. Accord Healthcare Ltd.
9.10.1. Company Overview
9.10.2. Financial Overview
9.10.3. Product Benchmarking
9.10.4. Key Developments

10. Key Insights

Content are not available

Choose License Type